MSI-H晚期结直肠癌一线治疗新标准,KEYNOTE-177结果发布 2020年6月29日,美国国家食品药品监督管理局(FDA)批准pembrolizumab(中文名为帕博利珠单抗,商品名Keytruda,简称K药)用于微卫星高度不稳定性(MSI-H)或错配修复缺陷(dMMR)用于不可切除或转移性结直肠癌(mCRC)患者的一线治疗。这是FDA首个批准单药用于一线治疗MS...
“[These data suggest that] we have an opportunity to cure some patients with immunotherapy,” said Andre. On June 29, 2020, the FDA approved the PD-1 inhibitor for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR CRC, based on data from the KEYNOTE-...
KEYNOTE: Creating Nanostructured Coatings to Improve Medical Device Performance while Obtaining Fast FDA ApprovalWebster, Thomas J